Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.64M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
300
-
Shares change
-
-25.4M
-
Total reported value, excl. options
-
$26.00
-
Value change
-
-$3.2M
-
Number of buys
-
1
-
Number of sells
-
-54
-
Price
-
$0.09
Significant Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q2 2025
57 filings reported holding LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2025.
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 300 shares
of 1.64M outstanding shares and own 0.02% of the company stock.
Largest 10 shareholders include IFP Advisors, Inc (300 shares), CWM, LLC (0 shares), SBI Securities Co., Ltd. (0 shares), NISA INVESTMENT ADVISORS, LLC (0 shares), Bank of New York Mellon Corp (0 shares), ProShare Advisors LLC (0 shares), Wilmington Savings Fund Society, FSB (0 shares), GEODE CAPITAL MANAGEMENT, LLC (0 shares), SG Americas Securities, LLC (0 shares), and Abel Hall, LLC (0 shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.